Mosaic ImmunoEngineering, Inc. (CPMV)

0.6000 0.0000 (0.00%) At close: 10:50AM EDT

Mosaic ImmunoEngineering, Inc.

1537 South Novato Blvd, #5
Novato, CA 94947
United States
657 208 0890
https://www.mosaicie.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 3

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Steven W. King	Chairman of the Board, President & CEO	267.84k	N/A	1964
Mr. Paul J. Lytle CPA	Executive VP, CFO, Secretary & Director	295.53k	N/A	1968
Mr. Joseph S. Shan M.P.H.	Head of Clinical Operations	N/A	N/A	1973
Dr. Marvin R. Garovoy M.D.	Head of Medical Immuno-Oncology	N/A	N/A	1944
Cyril Empig Ph.D.	Head of Vaccine Development	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

Corporate governance

Mosaic ImmunoEngineering, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.